The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human CD19. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to t2B4 signaling domains. And the vector product was designed for the treatment of Leukemia and Neuroblastoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC705||Lenti-CD19 CAR (scFv-CD28-CD3ζ, S2) Viral Particle|
|CAR-LC225||Anti-CD19 h(CD2-CD3ζ) CAR, pCDCAR1|
|CAR-LC273||Anti-CD19 h(CD3ζ, RXR/EcR) Conditional CAR, pCDCAR1|
|CAR-MZ098||Anti-CD19 (FMC-63) h(t2B4-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC630||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 104879) Viral Particle|
|CAR-LC012||Anti-CD19 (47G4) h(CD28-CD27-CD3ζ) CAR, pCDCAR1|
|CAR-NK-2-M328-4G||Anti-CD19 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1|
|CAR-LC369||Anti-CD19 (Inebilizumab) h(CD28-CD3ζ, Anti-CD47 ()) Armoured CAR, pCDCAR1|
|VP-CAR-LC517||Lenti-CD19 CAR (scFv-CD27-CD3ζ, 47G4) Viral Particle|
|CAR-MZ001||Anti-CD19 scFv h(CTLA4-CD3ζ) CAR, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved